Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced...
Covered in this story
What has happened since
- Incyte is down 5.4% since this was published, 39 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Incyte
- H.C. Wainwright: $125 → $152 by Sep 2027 · Buy via Investing.com
- Oppenheimer: $130 → $120 by Jul 2027 · Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INCY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Incyte →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.